• Company
  • News
  • Investors
  • Contacts
  • Careers
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Generic peptides
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Cosmetic
  • Individualized Peptides
  • Oligos
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Generic peptides
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Cosmetic
  • Individualized Peptides
  • Oligos
  • Home
  • News
  • Business news
  • New in-silico development tools support more efficient process design

New in-silico development tools support more efficient process design

8 December 2020
Business news
Pic graphic

The Polypeptide Group has developed a set of tools using Ypso-Proxima® software. They help make the most efficient choices at an early stage.

The field of Solid Phase Peptide Synthesis (SPPS) has boomed over the last few decades. But many companies are still relying on procedures used in the laboratory to achieve large-scale production. This has proven to be inefficient and not cost-effective. Not surprisingly, the overall quest to produce high-quality peptides at lower costs while meeting customers’ expectations for issues like cutting solvent consumption (and reducing environmental impact) without affecting the product quality has intensified.

Pharmaceutical manufacturers expect their CMDOs to deliver an efficient, yet robust and cost-optimized process for producing the final product. But a trial-and-error strategy that pushes the development of an optimal process later is not the most effective approach.

As part of an innovation program called “Advanced Peptide Synthesis,” the Polypeptide Group has developed a set of tools using Ypso-Proxima® software that helps its development chemists make the most efficient choices at an early stage. These tools include:

  • A predictive toolbox to preliminarily assess new peptides using a database with decades of accumulated knowledge
  • Simulation tools that represent complex peptide chemistry mechanisms and allow optimization of the process in silico

A chemist’s predictive toolbox

The structured database goes beyond basic information about molecular weight, hydrophobicity plot and the evolution of net charge with respect to pH. It aggregates information about peptide sequence edition, predictions of charges vs pH, mass spectra, conformation potential, solubility of peptides, impurity profile, and solvent consumption for downstream processes, which supports better selection of raw materials, and estimations of coupling times for given target peptide yield and purity. Confidence in the predictive results is increasing over time as more and more cases are fed to the database, including complex peptides with exotic motifs and exotic building blocks.

SPPS simulation tool

The simulation tool gives chemists answers to questions such as: what are the rate- determining steps within the set of reactions involved in a peptide synthesis, how to boost the reaction kinetics, and how to optimize the volume of solvent used? The simulation tools are based on results from measuring the evolution of a system over time and developing numerical models that are able to represent the reaction mechanisms.

Using these new in-silico development toolboxes, peptide chemists will be a step closer to being “right the first time” in their iterative development strategy.

See publication in Chemistry Today, issue September/October 2020 with Olivier Ludemann-Hombourger, Global Director Innovation & Technology, PolyPeptide Group, Strasbourg, France

 

Back to news

Related posts

9 November 2022

FluoGuide reaches milestone with FG001 for phase III clinical supply


Read more
28 June 2022

PolyPeptide wins Malmö Life Science Business Award


Read more
22 December 2021

Efficient and sustainable solutions for large scale peptide manufacturing


Read more

Polypeptide Group

INFO

COMPANY
LEADERSHIP
CONTACTS
CAREERS

NEWS

LATEST NEWS
SIGN UP FOR NEWS
EVENTS

SOCIALS

LINKEDIN
YOUTUBE
© Confidentiality 2021 PolyPeptide Group • Cookie management • Personal data • Sitemap • Confidentiality policy
      By clicking “Accept”, you consent to the use of ALL the cookies on our website . However you may visit Cookie Settings to provide a controlled consent.
      Cookie settingsACCEPT
      Privacy & Cookies Policy

      Privacy Overview

      You can enable or disable your consent for each category of cookie.

      More information on the collection of personal data
      Necessary
      Always Enabled

      The necessary cookies help to make a website usable by enabling basic functions such as page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

      Advertisement

      Marketing cookies are used to track visitors through websites. The goal is to display ads that are relevant and interesting to the individual user and therefore more valuable to third-party publishers and advertisers.

      Analytics

      Statistical cookies help website owners, through the anonymous collection and communication of information, to understand how visitors interact with websites.

      Performance

      Preferences cookies allow a website to retain information that changes the way the site behaves or displays, such as your preferred language or the region in which you are located.

      Save & Accept